S&P 500   2,515.94 (-97.16%)
DOW   21,280.04 (+1.61%)
QQQ   185.54 (+1.77%)
AAPL   242.81 (+0.79%)
FB   160.36 (+0.48%)
MSFT   154.05 (+1.28%)
GOOGL   1,113.15 (+1.00%)
AMZN   1,919.03 (+0.59%)
CGC   13.94 (+2.65%)
NVDA   252.92 (+4.05%)
BABA   189.64 (+1.11%)
MU   40.84 (+2.38%)
GE   7.18 (+1.85%)
TSLA   476.97 (-1.66%)
AMD   45.05 (+3.18%)
T   28.38 (+1.14%)
ACB   0.84 (+3.69%)
F   4.41 (+0.23%)
NFLX   366.23 (+0.59%)
BAC   20.45 (+3.44%)
GILD   74.97 (+3.39%)
DIS   95.96 (+1.10%)
S&P 500   2,515.94 (-97.16%)
DOW   21,280.04 (+1.61%)
QQQ   185.54 (+1.77%)
AAPL   242.81 (+0.79%)
FB   160.36 (+0.48%)
MSFT   154.05 (+1.28%)
GOOGL   1,113.15 (+1.00%)
AMZN   1,919.03 (+0.59%)
CGC   13.94 (+2.65%)
NVDA   252.92 (+4.05%)
BABA   189.64 (+1.11%)
MU   40.84 (+2.38%)
GE   7.18 (+1.85%)
TSLA   476.97 (-1.66%)
AMD   45.05 (+3.18%)
T   28.38 (+1.14%)
ACB   0.84 (+3.69%)
F   4.41 (+0.23%)
NFLX   366.23 (+0.59%)
BAC   20.45 (+3.44%)
GILD   74.97 (+3.39%)
DIS   95.96 (+1.10%)
S&P 500   2,515.94 (-97.16%)
DOW   21,280.04 (+1.61%)
QQQ   185.54 (+1.77%)
AAPL   242.81 (+0.79%)
FB   160.36 (+0.48%)
MSFT   154.05 (+1.28%)
GOOGL   1,113.15 (+1.00%)
AMZN   1,919.03 (+0.59%)
CGC   13.94 (+2.65%)
NVDA   252.92 (+4.05%)
BABA   189.64 (+1.11%)
MU   40.84 (+2.38%)
GE   7.18 (+1.85%)
TSLA   476.97 (-1.66%)
AMD   45.05 (+3.18%)
T   28.38 (+1.14%)
ACB   0.84 (+3.69%)
F   4.41 (+0.23%)
NFLX   366.23 (+0.59%)
BAC   20.45 (+3.44%)
GILD   74.97 (+3.39%)
DIS   95.96 (+1.10%)
S&P 500   2,515.94 (-97.16%)
DOW   21,280.04 (+1.61%)
QQQ   185.54 (+1.77%)
AAPL   242.81 (+0.79%)
FB   160.36 (+0.48%)
MSFT   154.05 (+1.28%)
GOOGL   1,113.15 (+1.00%)
AMZN   1,919.03 (+0.59%)
CGC   13.94 (+2.65%)
NVDA   252.92 (+4.05%)
BABA   189.64 (+1.11%)
MU   40.84 (+2.38%)
GE   7.18 (+1.85%)
TSLA   476.97 (-1.66%)
AMD   45.05 (+3.18%)
T   28.38 (+1.14%)
ACB   0.84 (+3.69%)
F   4.41 (+0.23%)
NFLX   366.23 (+0.59%)
BAC   20.45 (+3.44%)
GILD   74.97 (+3.39%)
DIS   95.96 (+1.10%)
Log in

NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News

$5.23
-0.07 (-1.32 %)
(As of 04/2/2020 11:49 AM ET)
Today's Range
$5.14
Now: $5.23
$5.41
50-Day Range
$4.27
MA: $7.96
$12.01
52-Week Range
$4.04
Now: $5.23
$19.80
Volume9,890 shs
Average Volume736,961 shs
Market Capitalization$256.95 million
P/E RatioN/A
Dividend YieldN/A
Beta2.18
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Read More
MacroGenics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.19 million
Book Value$4.71 per share

Profitability

Net Income$-151,810,000.00
Net Margins-236.51%

Miscellaneous

Employees364
Market Cap$256.95 million
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.


MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

How has MacroGenics' stock been impacted by COVID-19 (Coronavirus)?

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MGNX shares have decreased by 19.4% and is now trading at $5.23. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MacroGenics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating, 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for MacroGenics.

How were MacroGenics' earnings last quarter?

MacroGenics Inc (NASDAQ:MGNX) issued its quarterly earnings data on Tuesday, February, 25th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.71) by $0.10. The biopharmaceutical company had revenue of $25.19 million for the quarter, compared to analysts' expectations of $10.74 million. MacroGenics had a negative return on equity of 55.16% and a negative net margin of 236.51%. View MacroGenics' earnings history.

What price target have analysts set for MGNX?

12 brokers have issued 1 year target prices for MacroGenics' stock. Their forecasts range from $6.00 to $50.00. On average, they expect MacroGenics' share price to reach $18.91 in the next twelve months. This suggests a possible upside of 261.6% from the stock's current price. View analysts' price targets for MacroGenics.

Has MacroGenics been receiving favorable news coverage?

Press coverage about MGNX stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MacroGenics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutMacroGenics.

Are investors shorting MacroGenics?

MacroGenics saw a drop in short interest in February. As of February 28th, there was short interest totaling 3,670,000 shares, a drop of 5.2% from the February 13th total of 3,870,000 shares. Based on an average trading volume of 486,000 shares, the days-to-cover ratio is presently 7.6 days. Currently, 8.5% of the shares of the company are short sold. View MacroGenics' Current Options Chain.

Who are some of MacroGenics' key competitors?

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), NVIDIA (NVDA), TherapeuticsMD (TXMD), Incyte (INCY), Karyopharm Therapeutics (KPTI), Nektar Therapeutics (NKTR) and TG Therapeutics (TGTX).

Who are MacroGenics' key executives?

MacroGenics' management team includes the following people:
  • Dr. Scott Koenig, CEO, Pres & Director (Age 67)
  • Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)
  • Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)
  • Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57)

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $5.23.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $256.95 million and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe. View additional information about MacroGenics.

What is MacroGenics' official website?

The official website for MacroGenics is http://www.macquarie.com/.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.


MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  348 (Vote Outperform)
Underperform Votes:  360 (Vote Underperform)
Total Votes:  708
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel